Guidance regarding COVID‐19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Lisanne C. Verbruggen,Yuehan Wang,Saro H. Armenian,Matthew J. Ehrhardt,Helena J.H. Pal,Elvira C. Dalen,Jorrit W. van As,Edit Bardi,Katja Baust,Claire Berger,Elio Castagnola,Katie A. Devine,Judith Gebauer,Jordan Gilleland Marchak,Adam W. Glaser,Andreas H. Groll,Gabrielle M. Haeusler,Jaap den Hartogh,Riccardo Haupt,Lars Hjorth,Miho Kato,Tomáš Kepák,Maria M.W. Koopman,Thorsten Langer,Miho Maeda,Gisela Michel,Monica Muraca,Paul C. Nathan,Selina R. den Oever,Vesna Pavasovic,Satomi Sato,Fiona Schulte,Lillian Sung,Wim Tissing,Anne Uyttebroeck,Renée L. Mulder,Claudia Kuehni,Roderick Skinner,Melissa M. Hudson,Leontien C.M. Kremer,Maria M.W. (Rianne) Koopman
DOI: https://doi.org/10.1002/pbc.28702
2020-09-23
Abstract:Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID‐19. Little is known about the clinical course of COVID‐19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID‐19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID‐19.
oncology,pediatrics,hematology
What problem does this paper attempt to address?